ADAM proteases, ErbB pathways and cancer

Author： Zhou Bin-Bing S Fridman Jordan S Liu Xiangdong Friedman Steve M Newton Robert C Scherle Peggy A

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.14, Iss.6, 2005-06, pp. : 591-606

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The ErbB Receptors and their Ligands in Cancer: An Overview

Current Drug Targets, Vol. 6, Iss. 3, 2005-05 ,pp. : 243-257

Bentham Science Publishers

Access to resources Recommend Favorite

Irreversible Multitargeted ErbB Family Inhibitors for Therapy of Lung and Breast Cancer

Current Cancer Drug Targets, Vol. 14, Iss. 9, 2014-11 ,pp. : 775-793

Bentham Science Publishers

Access to resources Recommend Favorite

Inhibitors of erbB-1 kinase

Expert Opinion on Therapeutic Patents, Vol. 12, Iss. 12, 2002-12 ,pp. : 1903-1907

Informa Healthcare

Access to resources Recommend Favorite

Editorial [Hot Topic: ErbB Family and Downstream Signal Transduction Pathways as Targets for Anticancer Therapy (Guest Editor: F. Caponigro)]

Current Drug Targets, Vol. 6, Iss. 3, 2005-05 ,pp. : 241-242

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting ErbB Receptors in High-Grade Glioma

Current Pharmaceutical Design, Vol. 17, Iss. 23, 2011-08 ,pp. : 2468-2487

Bentham Science Publishers

Access to resources Recommend Favorite